Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection

Breast Cancer Clinical Trial

Official title:

A Single-Center, Open-Label Study Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05236387
• Other study ID #: IRB00154162
• Status: Terminated
• Start date: March 1, 2022
• Est. completion date: June 30, 2023

Study information

• Verified date: February 2024
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of the present study is to evaluate the ability of 99mTc-TM to identify the clipped node after neoadjuvant chemotherapy (NAC) and to compare this percentage with historical national data. This study will also evaluate pain and discomfort after injection and pathological features of clipped nodes and any additional nodes removed.

Description:

This is a phase 4 single-center, open-label, single-arm study evaluating the ability of 99mTc-TM to identify clipped nodes in primary breast cancer patients receiving NAC and subsequent Sentinel Lymph Node Biopsy (SLNB) as practice compared to published historical data . Sixty-four (64) patients (≥18 years) diagnosed with breast cancer and who are evaluated as having a favorable response (i.e., at least partial clinical response in the breast) to chemotherapy during the mid-treatment evaluation will be evaluated in this study. Patients will have suspicious lymph nodes assessed and one biopsied for pathological evaluation and clipped during the course of the patients' medical work-up. Patients will undergo NAC treatment and have a mid-treatment evaluation to assess response to the chemotherapy. Patients with a favorable response will complete NAC followed by identification of the clipped node and sentinel lymph nodes and standard lymph node assessment. Patients with an unfavorable response (i.e., no response to the NAC) will continue NAC but will not continue to participate in the study. All study patients undergoing SLNB will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) preoperatively. If no signal is detected within 30-60 minutes, patients may also be injected with BD (up to 10 cc), intraoperatively. Pain at injection site will be assessed pre-injection and at 1 minute after the 99mTc-TM injection.

It is anticipated that the majority of patients enrolled will receive NAC treatment. Although chemotherapy will be the primary neoadjuvant treatment used in this study, if the investigator feels the patient will benefit more from hormonal therapy, a hormonal treatment will be administered.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 14
• Est. completion date: June 30, 2023
• Est. primary completion date: May 23, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The patient has provided written informed consent with HIPAA authorization.

2. The patient is female or male and =18 years of age at the time of consent.

3. The patient has been diagnosed with invasive Stage 2-3 breast cancer (T1-3; N1-2).

4. The patient has no history of inflammatory breast cancer.

5. The patient has no matted node on examination (N3).

6. The patient is eligible for neoadjuvant chemotherapy (NAC).

7. The patient is a candidate for surgical intervention, with sentinel lymph node assessment being a part of the surgical plan.

8. If of childbearing potential, the patient has a negative pregnancy test within 48 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.

9. The patient has no known allergies or hypersensitivity to 99mTc-TM, BD, or India ink.

Exclusion Criteria:

1. The patient is pregnant or lactating.

2. The patient has clinical and/or radiological evidence of metastatic or systemic disease. Oligo metastatic disease is acceptable (one organ and controlled).

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• 99m Tc-TM
Each patient will receive a single injection (0.1 ml) of 99mTc-TM (50 mcg) at the upper outer skin of the breast using an intradermal technique confirmed by the presence of a skin wheal.

Locations

Country	Name	City	State
United States	Johns Hopkins Bayview Hospital	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Johns Hopkins University	Cardinal Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of clipped nodes detected with 99m Tc-Tm intraoperatively as determined with a hand held gamma detection device	The percentage of clipped nodes identified using 99mTc-TM will be calculated, along with an exact binomial 95% confidence interval.	1 month after the surgery
Secondary	Change in Pain at injection site as assessed by a visual analog scale	Pain Assessment will be performed before injecting 99m Tc-TM and approximately 1 minute after the injection. Injection site pain will be assessed using a standardized visual analog scale (VAS). The VAS is a horizontal line measuring 0-100 mm in length, anchored by word descriptors at each end. The left end (0 mm) is labeled "no pain" and the right end (100 mm) is labeled "worst pain imaginable". The patient will be instructed to make a vertical mark on the horizontal line that they feel represents their pain intensity. The VAS is scored manually by measurement in millimeters from the left side of the line (0 mm) to the point where the patient marks on the horizontal line.	Immediately before injection and at 1 minute after injection
Secondary	Number of clipped nodes that were SLNs	Number of clipped nodes that were Sentinel Lymph Nodes (SLNs).	1 month after the surgery
Secondary	Concordance of blue/hot nodes for clipped and SLNs as assessed by Lymphoseek with the highest counts on the Gamma counter	To study the pathological features of the clipped node and any additional nodes (attempt for 2-3 total sentinel lymph node assessment, as standard practice) identified by Lymphoseek with the highest counts on the Gamma counter (10% rule).	1 month after the surgery